Table. 250 mg: symptomatic treatment of chronic venous insufficiency; diabetic retinopathy.Table. 500 mg: clinical symptoms of chronic venous insufficiency of the lower limbs (pain, cramps, paraesthesia, swelling, skin changes on the background of blood stagnation); non-proliferative diabetic retinopathy.
Composition:
1 tabl contains 250 mg or 500 of Calcium dendezeate monohydrate. The preparation contains lactose.
Action:
The drug improves venous circulation and protects against blood vessels. It reduces the permeability and increases the elasticity of the capillaries. It reduces platelet aggregation and plasma viscosity, thus improving tissue flow, which prevents stasis and thrombosis in venous vessels. It acts antagonistically to autakoid and neurohormones (hitsamina, bradykinina). It improves the "plasticity" of erythrocytes and inhibits their tendency to stick together. Increases lymphatic drainage, at the same time reducing their fragility and permeability. It reduces the flow of fluids from the blood to the tissues and reduces swelling. The maximum concentration in blood reaches 6 hours after administration. It binds to 20-25% of plasma proteins. It is excreted in the urine and faeces (mainly unchanged, 10% of the dose - in the form of metabolites). T0,5 is about 5 hours.
Contraindications:
Hypersensitivity to the active substance or any of the excipients.
Precautions:
Use with caution in patients with gastric and duodenal ulcer disease, with recurrent gastritis and renal failure. In the case of severe renal failure, when dialysis is necessary, the dose should be reduced. Due to the risk of agranulocytosis, the patient should be informed that he should report to a doctor if any signs of infection occur. In this situation, it is necessary to check the blood counts along with the smear and stop using the preparation. The product contains lactose - should not be used in patients with galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.
Pregnancy and lactation:
The preparation can be used in pregnant women only if the potential benefit of the therapy outweighs the potential risk to the fetus. Calcium calcium bromate penetrates in very small amounts into breast milk; breastfeeding women should not use the product or should discontinue breast-feeding during treatment.
Side effects:
Very rare: agranulocytosis, itchy rash with erythema. In addition, you may experience: nausea, diarrhea, dizziness, drug-induced skin fever, joint pain.
Dosage:
Orally:Table. 250 mg. Depending on the type and severity of the disease, 1 tabl is given. 3 or 4 times a day during meals. The duration of treatment is usually from 3 weeks to 6 months. If necessary, the dose can be increased to 6 tablets. daily in divided doses.Table. 500 mg. Venous insufficiency: 1-2 tabl. per day. Non-proliferative diabetic retinopathy: 2-3 tabl. per day. Treatment may last from several weeks to several months depending on the indications. The product should be used after meals.
(C)
